What share amounts and prices were reported for CLPT?

Sales of 17,583 at $26.51 , 6,599 at $27.64 , 1,981 at $28.64 , and 300 at $29.21 were disclosed.

ClearPoint Neuro insider sales: tranches at $26.51 to $29.21 disclosed

Q: What price ranges applied to the weighted average CLPT sales?

Ranges were $26.07–$27.06 , $27.08–$28.07 , and $28.08–$29.05 for the first three tranches.

Q: What are Joseph M. Burnett’s CLPT holdings after the sales?

Post-transactions, 217,059 shares were owned indirectly by the trust, and 11,311 shares were owned directly.

Q: What is the insider’s relationship to CLPT?

Joseph M. Burnett is CEO and President and also a Director of ClearPoint Neuro, Inc.

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

ClearPoint Neuro (CLPT) CEO and President Joseph M. Burnett, also a Director, reported open‑market sales of Common Stock on 10/10/2025 under a Rule 10b5‑1 trading plan adopted on June 11, 2025.

Transactions disclosed: 17,583 shares at a weighted average price of $26.51 (range $26.07–$27.06); 6,599 shares at $27.64 (range $27.08–$28.07); 1,981 shares at $28.64 (range $28.08–$29.05); and 300 shares at $29.21.

Following these transactions, 217,059 shares were beneficially owned indirectly by the Joseph M. Burnett Trust (with Mr. Burnett as trustee), and 11,311 shares were owned directly.

Insider Trade Summary

Net Seller: 26,463 shares ($714,021)

Net Sell 5 txns

Insider BURNETT JOSEPH

Role CEO and President

Sold 26,463 shs ($714K)

Type	Security	Shares	Price	Value
Sale	Common Stock	17,583	$26.51	$466K
Sale	Common Stock	6,599	$27.64	$182K
Sale	Common Stock	1,981	$28.64	$57K
Sale	Common Stock	300	$29.21	$9K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 225,939 shares (Indirect, See Footnote); Common Stock — 11,311 shares (Direct)

Footnotes (1)

The sale of shares reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1. Represents a weighted average sales price per share. The shares were sold at prices ranging from $26.07 to $27.06. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust. Represents a weighted average sales price per share. The shares were sold at prices ranging from $27.08 to $28.07. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $28.08 to $29.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 10/14/2025 - 04:33 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

BURNETT JOSEPH

(Last)

(First)

(Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH

92075

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
10/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/10/2025		S⁽¹⁾		17,583	D	$26.51⁽²⁾	225,939	I	See Footnote⁽³⁾
Common Stock	10/10/2025		S⁽¹⁾		6,599	D	$27.64⁽⁴⁾	219,340	I	See Footnote⁽³⁾
Common Stock	10/10/2025		S⁽¹⁾		1,981	D	$28.64⁽⁵⁾	217,359	I	See Footnote⁽³⁾
Common Stock	10/10/2025		S⁽¹⁾		300	D	$29.21	217,059	I	See Footnote⁽³⁾
Common Stock								11,311	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sale of shares reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1.

2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $26.07 to $27.06. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

3. These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust.

4. Represents a weighted average sales price per share. The shares were sold at prices ranging from $27.08 to $28.07. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

5. Represents a weighted average sales price per share. The shares were sold at prices ranging from $28.08 to $29.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

	/s/ Danilo D'Alessandro, by Power of Attorney for Joseph M. Burnett	10/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did CLPT disclose?

CEO and President Joseph M. Burnett reported sales of ClearPoint Neuro Common Stock on 10/10/2025 across four tranches.

Were the CLPT insider trades under a 10b5-1 plan?

Yes. The sales were made under a written trading plan adopted on June 11, 2025 in accordance with Rule 10b5‑1.

What price ranges applied to the weighted average CLPT sales?

Ranges were $26.07–$27.06, $27.08–$28.07, and $28.08–$29.05 for the first three tranches.

What are Joseph M. Burnett’s CLPT holdings after the sales?

Post-transactions, 217,059 shares were owned indirectly by the trust, and 11,311 shares were owned directly.

What is the insider’s relationship to CLPT?

Joseph M. Burnett is CEO and President and also a Director of ClearPoint Neuro, Inc.